Home › Lung Cancer › NCT03290534

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Subject signed inform consent
* Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung
* Pre-operative criteria
* Lung nodule suspicious for NSCLC
* Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen
* Clinical stage I or Clinical stage II
* Not pregnant or nursing
* Negative pregnancy test in premenopausal women
* Fertile patients must use effective contraception
* More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer

Exclusion Criteria:

\-

About the study

This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.

What is being tested

• CivaSheet (device)

Sponsor: CivaTech Oncology · Participants: 40 · Started: Mar 13, 2019

Contact the study team

Official record on ClinicalTrials.gov — NCT03290534

Locations in the U.S.

Conditions

• Lung Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.